دورية أكاديمية
أعرض في EDS

Ivermectin-Loaded Mesoporous Silica and Polymeric Nanocapsules: Impact on Drug Loading, In Vitro Solubility Enhancement, and Release Performance.

التفاصيل البيبلوغرافية
العنوان: Ivermectin-Loaded Mesoporous Silica and Polymeric Nanocapsules: Impact on Drug Loading, In Vitro Solubility Enhancement, and Release Performance.
المؤلفون: Velho MC; Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre 90610-000, RS, Brazil.; Laboratório de Nanocarreadores e Impressão 3D em Tecnologia Farmacêutica (Nano3D), Faculdade de Farmácia-UFRGS, Av. Ipiranga, 2752, 4° Andar, Porto Alegre 90610-000, RS, Brazil., Funk NL; Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre 90610-000, RS, Brazil.; Laboratório de Nanocarreadores e Impressão 3D em Tecnologia Farmacêutica (Nano3D), Faculdade de Farmácia-UFRGS, Av. Ipiranga, 2752, 4° Andar, Porto Alegre 90610-000, RS, Brazil., Deon M; Laboratório de Nanocarreadores e Impressão 3D em Tecnologia Farmacêutica (Nano3D), Faculdade de Farmácia-UFRGS, Av. Ipiranga, 2752, 4° Andar, Porto Alegre 90610-000, RS, Brazil.; Programa de Pós-Graduação em Biociências, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Porto Alegre 90050-170, RS, Brazil., Benvenutti EV; Laboratório de Sólidos e Superfícies, Instituto de Química-UFRGS, Porto Alegre 90650-001, RS, Brazil., Buchner S; Laboratório de Altas Pressões e Materiais Avançados (LAPMA), Instituto de Física-UFRGS, Porto Alegre 91501-970, RS, Brazil., Hinrichs R; Instituto de Geociências (IGEO)-UFRGS, Porto Alegre 90650-001, RS, Brazil., Pilger DA; Laboratório de Análises Bioquímicas e Citológicas, Faculdade de Farmácia-UFRGS, Porto Alegre 90610-000, RS, Brazil., Beck RCR; Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre 90610-000, RS, Brazil.; Laboratório de Nanocarreadores e Impressão 3D em Tecnologia Farmacêutica (Nano3D), Faculdade de Farmácia-UFRGS, Av. Ipiranga, 2752, 4° Andar, Porto Alegre 90610-000, RS, Brazil.
المصدر: Pharmaceutics [Pharmaceutics] 2024 Feb 26; Vol. 16 (3). Date of Electronic Publication: 2024 Feb 26.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101534003 Publication Model: Electronic Cited Medium: Print ISSN: 1999-4923 (Print) Linking ISSN: 19994923 NLM ISO Abbreviation: Pharmaceutics Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI
مستخلص: Ivermectin (IVM), a widely used drug for parasitic infections, faces formulation and application challenges due to its poor water solubility and limited bioavailability. Pondering the impact of IVM's high partition coefficient value (log P) on its drug release performance, it is relevant to explore whether IVM nanoencapsulation in organic or inorganic nanoparticles would afford comparable enhanced aqueous solubility. To date, the use of inorganic nanoparticles remains an unexplored approach for delivering IVM. Therefore, here we loaded IVM in mesoporous silica particles (IVM-MCM), as inorganic nanomaterial, and in well-known poly(ε-caprolactone) nanocapsules (IVM-NC). IVM-MCM had a well-organized hexagonal mesoporous structure, reduced surface area, and high drug loading of 10% w / w . IVM-NC had a nanometric mean size (196 nm), high encapsulation efficiency (100%), physicochemical stability as an aqueous dispersion, and drug loading of 0.1% w / w . Despite differing characteristics, both nanoencapsulated forms enhance IVM's aqueous intrinsic solubility compared to a crystalline IVM: after 72 h, IVM-MCM and IVM-NC achieve 72% and 78% releases through a dialysis bag, whereas crystalline IVM dispersion achieves only 40% drug diffusion. These results show distinct controlled release profiles, where IVM-NC provides a deeper sustained controlled release over the whole experiment compared to the inorganic nanomaterial (IVM-MCM). Discussing differences, including drug loading and release kinetics, is crucial for optimizing IVM's therapeutic performance. The study design, combined with administration route plans and safety considerations for humans and animals, may expedite the rational optimization of IVM nanoformulations for swift clinical translation.
References: Pharm Dev Technol. 2022 Oct;27(8):865-880. (PMID: 36062978)
ACS Nano. 2019 Oct 22;13(10):11034-11048. (PMID: 31603314)
Parasit Vectors. 2019 Oct 10;12(1):469. (PMID: 31601244)
Antimicrob Agents Chemother. 2013 Feb;57(2):1040-6. (PMID: 23165468)
Int J Pharm. 2023 May 25;639:122965. (PMID: 37084836)
Pharmaceutics. 2021 Jan 24;13(2):. (PMID: 33498885)
Acta Pharm Sin B. 2018 Mar;8(2):165-177. (PMID: 29719777)
Parasitol Res. 2017 Aug;116(8):2111-2117. (PMID: 28523490)
Biochem J. 2012 May 1;443(3):851-6. (PMID: 22417684)
Inflamm Res. 2011 Jun;60(6):589-96. (PMID: 21279416)
Toxicol Appl Pharmacol. 2022 Aug 15;449:116073. (PMID: 35605787)
Int J Antimicrob Agents. 2019 Aug;54(2):134-142. (PMID: 31071469)
Eur J Pharm Sci. 2020 Jan 15;142:105103. (PMID: 31648050)
Recent Pat Drug Deliv Formul. 2012 Dec;6(3):195-208. (PMID: 22845040)
Biophys Rev. 2016 Dec;8(4):409-427. (PMID: 28510011)
Pharmaceutics. 2021 Aug 23;13(8):. (PMID: 34452279)
AAPS PharmSciTech. 2019 Aug 12;20(7):283. (PMID: 31407115)
Eur J Pharm Sci. 2015 Nov 15;79:36-43. (PMID: 26342772)
Expert Opin Drug Deliv. 2010 Apr;7(4):429-44. (PMID: 20331353)
AAPS PharmSciTech. 2018 May;19(4):1637-1646. (PMID: 29500762)
Pharmacol Res. 2021 Jan;163:105207. (PMID: 32971268)
Pharmaceutics. 2022 Feb 10;14(2):. (PMID: 35214122)
J Antimicrob Chemother. 2012 Aug;67(8):1884-94. (PMID: 22535622)
Molecules. 2022 Sep 17;27(18):. (PMID: 36144803)
Parasit Vectors. 2018 May 4;11(1):287. (PMID: 29728135)
Eur J Pharm Biopharm. 2004 May;57(3):533-40. (PMID: 15093603)
Mater Sci Eng C Mater Biol Appl. 2019 Dec;105:110073. (PMID: 31546444)
Int J Pharm. 2022 May 25;620:121750. (PMID: 35421531)
Antimicrob Resist Infect Control. 2018 Feb 20;7:27. (PMID: 29468054)
Eur J Pharm Biopharm. 2003 Nov;56(3):501-5. (PMID: 14602195)
Chem Eng Sci. 2015 Mar 24;125:75-84. (PMID: 25684779)
Am J Cancer Res. 2018 Feb 01;8(2):317-331. (PMID: 29511601)
J Control Release. 2006 Mar 10;111(1-2):81-8. (PMID: 16388871)
Clin Cosmet Investig Dermatol. 2016 Mar 18;9:71-7. (PMID: 27051311)
Folia Med (Plovdiv). 2018 Dec 1;60(4):580-593. (PMID: 31188767)
Sci Rep. 2014 Jan 14;4:3682. (PMID: 24419589)
PLoS Negl Trop Dis. 2015 Mar 05;9(3):e0003549. (PMID: 25742173)
Biomed Pharmacother. 2022 Sep;153:113410. (PMID: 36076536)
Carbohydr Polym. 2019 Jun 15;214:131-141. (PMID: 30925981)
Nanotechnology. 2020 Aug 21;31(34):345705. (PMID: 32392541)
Artif Cells Nanomed Biotechnol. 2018 Mar;46(2):255-262. (PMID: 28368657)
Anal Chem. 2016 Jul 19;88(14):7014-22. (PMID: 27329347)
Antiviral Res. 2020 Jun;178:104787. (PMID: 32251768)
Pharmaceutics. 2022 Jul 29;14(8):. (PMID: 36015204)
Nanomaterials (Basel). 2020 Jul 19;10(7):. (PMID: 32707641)
AAPS PharmSciTech. 2017 Feb;18(1):212-223. (PMID: 26956145)
Chem Pharm Bull (Tokyo). 2018;66(3):327-333. (PMID: 29491265)
Expert Opin Drug Deliv. 2013 May;10(5):623-38. (PMID: 23387432)
Acta Pharm Sin B. 2015 Sep;5(5):442-53. (PMID: 26579474)
Molecules. 2020 Aug 15;25(16):. (PMID: 32824172)
Biochem Biophys Res Commun. 2018 Feb 26;497(1):241-247. (PMID: 29428725)
Parasitol Res. 2014 Feb;113(2):681-91. (PMID: 24366812)
Eur J Pharm Biopharm. 2019 Mar;136:9-17. (PMID: 30630060)
Mater Sci Eng C Mater Biol Appl. 2020 Jun;111:110753. (PMID: 32279762)
Int J Pharm. 2008 Jul 9;359(1-2):288-93. (PMID: 18495390)
Bioorg Med Chem Lett. 2019 Jul 1;29(13):1549-1554. (PMID: 31054863)
Pharmaceutics. 2022 Dec 21;15(1):. (PMID: 36678649)
Nanomedicine (Lond). 2019 Aug;14(16):2243-2267. (PMID: 31411537)
معلومات مُعتمدة: 406436/2022-3 National Council for Scientific and Technological Development; Finance Code 001 Coordenação de Aperfeicoamento de Pessoal de Nível Superior; 23/2551-0000507-7 Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul
فهرسة مساهمة: Keywords: enhanced solubility; ivermectin; nanoparticles; silica
تواريخ الأحداث: Date Created: 20240328 Latest Revision: 20240330
رمز التحديث: 20240330
مُعرف محوري في PubMed: PMC10974340
DOI: 10.3390/pharmaceutics16030325
PMID: 38543218
قاعدة البيانات: MEDLINE
الوصف
تدمد:1999-4923
DOI:10.3390/pharmaceutics16030325